Taiwan innovations need "positive discrimination"
This article was originally published in Clinica
Executive Summary
Exporters of high-tech medical devices to Taiwan are hoping that the forthcoming new system of global budgeting for hospitals will be transparent and adequately funded. This is essential, says consultant Ed Rozynski, in order that medical technology advances are rewarded. This is not the case with the current system, where the pricing mechanism effectively discourages innovations.
You may also be interested in...
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.